Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac - LARVOL DELTA

Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis. (PubMed, Mol Cancer) - "Combined ALECSAT and anti-PDL1 therapy results in favorable anti-cancer responses in both cell line-derived xenograft and autologous PDX models of advanced triple-negative breast cancer."

Combination therapy • Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma. (PubMed, Neurooncol Adv) - "The treatment groups were balanced in terms of serious adverse events (52.4% vs 52.5%), but adverse events ≥grade 3 were more common in the experimental arm (81.0% vs 92.5%). Addition of ALECSAT immunotherapy to standard treatment with radiochemotherapy was well tolerated but did not improve PFS or OS for patients with newly diagnosed GBM."

Clinical • Journal • P2 data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

ImmunoBreast - A Phase Ib Study (clinicaltrials.gov) - P1/2; N=20; Recruiting; Sponsor: Henrik Ditzel

Clinical • New P1/2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2

Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma (clinicaltrials.gov) - P2; N=62; Completed; Sponsor: CytoVac A/S; Active, not recruiting ➔ Completed; Trial completion date: Jun 2021 ➔ Feb 2020; Trial primary completion date: Jun 2020 ➔ Nov 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma (clinicaltrials.gov) - P2; N=62; Active, not recruiting; Sponsor: CytoVac A/S; Recruiting ➔ Active, not recruiting; Trial completion date: Jan 2022 ➔ Jun 2021; Trial primary completion date: Jan 2020 ➔ Jun 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date

A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients (clinicaltrials.gov) - P1; N=10; Completed; Sponsor: CytoVac A/S; Terminated ➔ Completed

Clinical • Trial completion